Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

This study compares two treatments for liver cancer (hepatocellular carcinoma) that cannot be surgically removed: combining TACE (a procedure that delivers chemotherapy directly to the liver tumor while cutting off its blood supply) with lenvatinib (an oral targeted therapy drug) versus lenvatinib alone. **You may be eligible if...** - You are between 18 and 75 years old - You have been confirmed to have hepatocellular carcinoma (HCC) by CT/MRI or biopsy - Your liver cancer is early to intermediate-advanced stage (BCLC A, B subgroup B, or C) with no prior treatment - You have at least one measurable tumor - Your daily functioning is reasonable (ECOG 0-2) **You may NOT be eligible if...** - Your liver cancer has spread extensively with more than 10 tumors or more than 50% liver involvement - You have a blood clot in the main portal vein (the major vessel supplying the liver) - Your liver function is severely impaired (Child-Pugh score 10 or above / ALBI grade 3) - You have uncontrolled high blood pressure, a recent heart attack, or blood clotting disorders - You have a known allergy or intolerance to lenvatinib Talk to your doctor to see if this trial is right for you.